Alector - ALEC Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares.
View ALEC analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year price objectives for Alector's shares. Their ALEC share price forecasts range from $6.00 to $41.00. On average, they expect the company's share price to reach $15.38 in the next year. This suggests a possible upside of 152.0% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.9% and is now trading at $6.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ALEC earnings forecast.

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.09. The firm had revenue of $14.44 million for the quarter, compared to analyst estimates of $35.37 million. Alector had a negative net margin of 99.77% and a negative trailing twelve-month return on equity of 52.10%.

ETFs with the largest weight of Alector (NASDAQ:ALEC) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Alector updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $15.00 million-$25.00 million, compared to the consensus revenue estimate of $25.39 million.

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (2.93%), Price T Rowe Associates Inc. MD (2.09%), Franklin Resources Inc. (1.93%), Geode Capital Management LLC (1.44%), Braidwell LP (0.88%) and Morgan Stanley (0.72%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Shehnaaz Suliman and Terrance Mcguire.
View institutional ownership trends.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALEC stock can currently be purchased for approximately $6.10.

Alector (NASDAQ:ALEC) has a market capitalization of $506.48 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

The company employs 208 workers across the globe.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.